ARTICLE | Company News
Novartis returning Enanta's HCV compound
October 2, 2014 2:57 AM UTC
Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) saidNovartis AG (NYSE:NVS; SIX:NOVN) will return rights to the biotech's EDP-239, an HCV non-structural protein 5A (NS5A) inhibitor that is in Phase I testing, as the pharma exits the HCV business.
Novartis acquired exclusive, worldwide rights to EDP-239 in February 2012. Enanta received $34 million up front and an $11 million milestone payment in January 2013. ...